20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine". A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
The strategy in pharmaceuticals has switched from blockbuster M&A deals towards smaller targets. This trend highlights increased drug approvals by the FDA. Drug approvals have continued to grow year on year.
"We expect approvals to remain relatively strong in the intermediate term, despite lagging during the first four months of 2016," Fitch reported.
Big pharma is looking for smaller biotech and therapeutics companies to increase their drug portfolios. With big M&A deals being in a very critical environment, this seems to be the winning strategy for large firms. Even with acquisitions, companies will still focus on "innovative treatment platforms" due to "positive trends in drug development pipelines, new product commercialization and moderating patent expiry risks," Fitch noted.
Recent Big Pharma acquisitions
- Pfizer Inc. (NYSE: PFE) announced it would buy Anacor Pharmaceuticals Inc. (NASDAQ: ANAC).
- Bristol-Myers Squibb's Co (NYSE: BMY) acquisition of Padlock therapeutics.
- Eli Lilly and Co's (NYSE: LLY) acquisition of Glycostasis Inc.
20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine". A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!